Back to Directory
Albiglutide
Metabolic & Weight ManagementLong-acting GLP-1 receptor agonist, withdrawn from market but historically significant.
Key Benefits
- ✓Improved glycemic control
- ✓Weight loss
- ✓Once-weekly dosing
- ✓Cardiovascular benefits shown
Dosing Information
Dosage Range
30-50 mg
Frequency
Once weekly
Typical Duration
Was ongoing
Detailed Protocol
Was administered via subcutaneous injection once weekly. Withdrawn from market in 2018.
About Albiglutide
Albiglutide (Tanzeum) was a GLP-1 receptor agonist fused to human albumin, allowing once-weekly dosing. It was FDA-approved for type 2 diabetes but voluntarily withdrawn from market in 2018 for business reasons, not safety concerns.
Research Notes
FDA-approved 2014, withdrawn 2018 for business reasons. HARMONY-Outcomes trial showed cardiovascular benefits. No longer available.
Potential Side Effects
- •Nausea
- •Injection site reactions
- •Upper respiratory infections
- •Diarrhea
Always consult with a healthcare professional before starting any peptide therapy.